Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Jul 1;180(1):191–201. doi: 10.1084/jem.180.1.191

CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis

PMCID: PMC2191568  PMID: 7516406

Abstract

The glycosphingolipid globotriaosyl ceramide (CD77) and other globo- series glycolipids containing terminal galactose (Gal)alpha 1-4Gal residues function as receptors for the verotoxin (Shiga-like toxin) family of Escherichia coli-elaborated toxins. CD77 is also a marker for germinal center B lymphocytes and Burkitt's lymphoma cells. The pan B cell marker CD19 is a 95-kD membrane protein that appears early in B cell differentiation and is only lost upon terminal differentiation to plasma cells. CD19 is involved in signal transduction and has a regulatory role in B cell proliferation and differentiation in response to activation in vitro. However, an endogenous ligand for CD19 has not yet been identified. We report herein that the extracellular domain of CD19 has a potential CD77-binding site with extensive sequence similarity to the verotoxin B-subunits. These B-subunit-like sequences on CD19 are in close proximity following the organization of intervening amino acids into disulfide-linked domains. Cocapping of CD19 and CD77 on Burkitt's lymphoma-derived Daudi cells with anti-CD19 antibodies indicates that CD19 and CD77 are associated on the B cell surface. Cell surface binding of anti-CD19 antibodies is decreased on CD77-deficient mutant Daudi cells, suggesting that CD77 expression influences the surface expression of CD19. Wild-type Daudi cells, but not the CD19/CD77-deficient mutants, bind to matrices expressing the carbohydrate moiety of CD77 or other Gal alpha 1-4Gal containing glycolipids. This binding can be inhibited by anti-CD77 antibodies, the CD77-binding verotoxin B-subunit or anti-CD19 antibodies. Daudi cells exhibit a degree of spontaneous homotypic adhesion in culture while the CD77/CD19-deficient Daudi mutants grow as single cells. The stronger homotypic adhesion that occurs in B cells after antibody ligation of CD19 and that involves, to some extent, the integrin system, is also dramatically lower in the mutant cells relative to the parent cell line. However, reconstitution of mutant cells with CD77 restores the anti-CD19 mAb-induced adhesion to wild-type Daudi cell levels. These studies represent the first time that CD19-mediated signaling has been reconstituted in a low-responder B cell line. These convergent observations provide compelling evidence that CD19/CD77 interactions function in adhesion and signal transduction at a specific stage in B cell development and suggest that such interactions have a role in B lymphocyte homing and germinal center formation in vivo. By targeting CD77+ B cells, verotoxins may suppress the humoral arm of the immune response during infection.(ABSTRACT TRUNCATED AT 400 WORDS)

Full Text

The Full Text of this article is available as a PDF (2.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong G. D., Fodor E., Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J Infect Dis. 1991 Dec;164(6):1160–1167. doi: 10.1093/infdis/164.6.1160. [DOI] [PubMed] [Google Scholar]
  2. Boyd B., Tyrrell G., Maloney M., Gyles C., Brunton J., Lingwood C. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs. J Exp Med. 1993 Jun 1;177(6):1745–1753. doi: 10.1084/jem.177.6.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bradbury L. E., Goldmacher V. S., Tedder T. F. The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. J Immunol. 1993 Sep 15;151(6):2915–2927. [PubMed] [Google Scholar]
  4. Bradbury L. E., Kansas G. S., Levy S., Evans R. L., Tedder T. F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol. 1992 Nov 1;149(9):2841–2850. [PubMed] [Google Scholar]
  5. Callard R. E., Rigley K. P., Smith S. H., Thurstan S., Shields J. G. CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used. J Immunol. 1992 May 15;148(10):2983–2987. [PubMed] [Google Scholar]
  6. Carter R. H., Fearon D. T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992 Apr 3;256(5053):105–107. doi: 10.1126/science.1373518. [DOI] [PubMed] [Google Scholar]
  7. Carter R. H., Tuveson D. A., Park D. J., Rhee S. G., Fearon D. T. The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol. 1991 Dec 1;147(11):3663–3671. [PubMed] [Google Scholar]
  8. Cohen A., Hannigan G. E., Williams B. R., Lingwood C. A. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem. 1987 Dec 15;262(35):17088–17091. [PubMed] [Google Scholar]
  9. Cohen A., Madrid-Marina V., Estrov Z., Freedman M. H., Lingwood C. A., Dosch H. M. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990;2(1):1–8. doi: 10.1093/intimm/2.1.1. [DOI] [PubMed] [Google Scholar]
  10. De Grandis S., Ginsberg J., Toone M., Climie S., Friesen J., Brunton J. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol. 1987 Sep;169(9):4313–4319. doi: 10.1128/jb.169.9.4313-4319.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DeGrandis S., Law H., Brunton J., Gyles C., Lingwood C. A. Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem. 1989 Jul 25;264(21):12520–12525. [PubMed] [Google Scholar]
  12. Donohue-Rolfe A., Jacewicz M., Keusch G. T. Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol Microbiol. 1989 Sep;3(9):1231–1236. doi: 10.1111/j.1365-2958.1989.tb00273.x. [DOI] [PubMed] [Google Scholar]
  13. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988 Jan 15;171(1-2):45–50. doi: 10.1111/j.1432-1033.1988.tb13756.x. [DOI] [PubMed] [Google Scholar]
  14. Evans S. S., Collea R. P., Leasure J. A., Lee D. B. IFN-alpha induces homotypic adhesion and Leu-13 expression in human B lymphoid cells. J Immunol. 1993 Feb 1;150(3):736–747. [PubMed] [Google Scholar]
  15. Gillard B. K., Jones M. A., Turner A. A., Lewis D. E., Marcus D. M. Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids. Arch Biochem Biophys. 1990 May 15;279(1):122–129. doi: 10.1016/0003-9861(90)90471-a. [DOI] [PubMed] [Google Scholar]
  16. Gregory C. D., Edwards C. F., Milner A., Wiels J., Lipinski M., Rowe M., Tursz T., Rickinson A. B. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int J Cancer. 1988 Aug 15;42(2):213–220. doi: 10.1002/ijc.2910420212. [DOI] [PubMed] [Google Scholar]
  17. Gregory C. D., Tursz T., Edwards C. F., Tetaud C., Talbot M., Caillou B., Rickinson A. B., Lipinski M. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol. 1987 Jul 1;139(1):313–318. [PubMed] [Google Scholar]
  18. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G. T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med. 1986 Jun 1;163(6):1391–1404. doi: 10.1084/jem.163.6.1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jackson M. P., Wadolkowski E. A., Weinstein D. L., Holmes R. K., O'Brien A. D. Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis. J Bacteriol. 1990 Feb;172(2):653–658. doi: 10.1128/jb.172.2.653-658.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kansas G. S., Tedder T. F. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol. 1991 Dec 15;147(12):4094–4102. [PubMed] [Google Scholar]
  21. Karmali M. A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989 Jan;2(1):15–38. doi: 10.1128/cmr.2.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Keusch G. T., Jacewicz M., Levine M. M., Hornick R. B., Kochwa S. Pathogenesis of shigella diarrhea. Serum anticytotoxin antibody response produced by toxigenic and nontoxigenic Shigella dysenteriae 1. J Clin Invest. 1976 Jan;57(1):194–202. doi: 10.1172/JCI108259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lindberg A. A., Brown J. E., Strömberg N., Westling-Ryd M., Schultz J. E., Karlsson K. A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem. 1987 Feb 5;262(4):1779–1785. [PubMed] [Google Scholar]
  24. Lingwood C. A., Law H., Richardson S., Petric M., Brunton J. L., De Grandis S., Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987 Jun 25;262(18):8834–8839. [PubMed] [Google Scholar]
  25. Lingwood C. A. Verotoxin-binding in human renal sections. Nephron. 1994;66(1):21–28. doi: 10.1159/000187761. [DOI] [PubMed] [Google Scholar]
  26. Lingwood C. A. Verotoxins and their glycolipid receptors. Adv Lipid Res. 1993;25:189–211. [PubMed] [Google Scholar]
  27. Lingwood C. A., Yiu S. K. Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit. Biochem J. 1992 Apr 1;283(Pt 1):25–26. doi: 10.1042/bj2830025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Louise C. B., Obrig T. G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun. 1991 Nov;59(11):4173–4179. doi: 10.1128/iai.59.11.4173-4179.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. MacLeod D. L., Gyles C. L., Wilcock B. P. Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet Pathol. 1991 Jan;28(1):66–73. doi: 10.1177/030098589102800109. [DOI] [PubMed] [Google Scholar]
  30. Mangeney M., Lingwood C. A., Taga S., Caillou B., Tursz T., Wiels J. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993 Nov 1;53(21):5314–5319. [PubMed] [Google Scholar]
  31. Mangeney M., Richard Y., Coulaud D., Tursz T., Wiels J. CD77: an antigen of germinal center B cells entering apoptosis. Eur J Immunol. 1991 May;21(5):1131–1140. doi: 10.1002/eji.1830210507. [DOI] [PubMed] [Google Scholar]
  32. Matsumoto A. K., Martin D. R., Carter R. H., Klickstein L. B., Ahearn J. M., Fearon D. T. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med. 1993 Oct 1;178(4):1407–1417. doi: 10.1084/jem.178.4.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Murray L. J., Habeshaw J. A., Wiels J., Greaves M. F. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer. 1985 Nov 15;36(5):561–565. doi: 10.1002/ijc.2910360508. [DOI] [PubMed] [Google Scholar]
  34. Murzin A. G. OB(oligonucleotide/oligosaccharide binding)-fold: common structural and functional solution for non-homologous sequences. EMBO J. 1993 Mar;12(3):861–867. doi: 10.1002/j.1460-2075.1993.tb05726.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nadler L. M., Anderson K. C., Marti G., Bates M., Park E., Daley J. F., Schlossman S. F. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983 Jul;131(1):244–250. [PubMed] [Google Scholar]
  36. Nudelman E., Kannagi R., Hakomori S., Parsons M., Lipinski M., Wiels J., Fellous M., Tursz T. A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. Science. 1983 Apr 29;220(4596):509–511. doi: 10.1126/science.6836295. [DOI] [PubMed] [Google Scholar]
  37. O'Brien A. D., Holmes R. K. Shiga and Shiga-like toxins. Microbiol Rev. 1987 Jun;51(2):206–220. doi: 10.1128/mr.51.2.206-220.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Obrig T. G., Louise C. B., Lingwood C. A., Boyd B., Barley-Maloney L., Daniel T. O. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem. 1993 Jul 25;268(21):15484–15488. [PubMed] [Google Scholar]
  39. Perera L. P., Samuel J. E., Holmes R. K., O'Brien A. D. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity. J Bacteriol. 1991 Feb;173(3):1151–1160. doi: 10.1128/jb.173.3.1151-1160.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pesando J. M., Bouchard L. S., McMaster B. E. CD19 is functionally and physically associated with surface immunoglobulin. J Exp Med. 1989 Dec 1;170(6):2159–2164. doi: 10.1084/jem.170.6.2159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Ramotar K., Boyd B., Tyrrell G., Gariepy J., Lingwood C., Brunton J. Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron. Biochem J. 1990 Dec 15;272(3):805–811. doi: 10.1042/bj2720805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Samuel J. E., Perera L. P., Ward S., O'Brien A. D., Ginsburg V., Krivan H. C. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect Immun. 1990 Mar;58(3):611–618. doi: 10.1128/iai.58.3.611-618.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sandvig K., Garred O., Prydz K., Kozlov J. V., Hansen S. H., van Deurs B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 1992 Aug 6;358(6386):510–512. doi: 10.1038/358510a0. [DOI] [PubMed] [Google Scholar]
  44. Sandvig K., Prydz K., Ryd M., van Deurs B. Endocytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells. J Cell Biol. 1991 May;113(3):553–562. doi: 10.1083/jcb.113.3.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Saxena S. K., O'Brien A. D., Ackerman E. J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem. 1989 Jan 5;264(1):596–601. [PubMed] [Google Scholar]
  46. Schriever F., Freedman A. S., Freeman G., Messner E., Lee G., Daley J., Nadler L. M. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med. 1989 Jun 1;169(6):2043–2058. doi: 10.1084/jem.169.6.2043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Smith S. H., Rigley K. P., Callard R. E. Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms. Immunology. 1991 Jul;73(3):293–297. [PMC free article] [PubMed] [Google Scholar]
  48. Stamenkovic I., Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med. 1988 Sep 1;168(3):1205–1210. doi: 10.1084/jem.168.3.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tedder T. F., Isaacs C. M. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol. 1989 Jul 15;143(2):712–717. [PubMed] [Google Scholar]
  50. Tyrrell D., James P., Rao N., Foxall C., Abbas S., Dasgupta F., Nashed M., Hasegawa A., Kiso M., Asa D. Structural requirements for the carbohydrate ligand of E-selectin. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10372–10376. doi: 10.1073/pnas.88.22.10372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tyrrell G. J., Ramotar K., Toye B., Boyd B., Lingwood C. A., Brunton J. L. Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):524–528. doi: 10.1073/pnas.89.2.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Uckun F. M., Burkhardt A. L., Jarvis L., Jun X., Stealey B., Dibirdik I., Myers D. E., Tuel-Ahlgren L., Bolen J. B. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J Biol Chem. 1993 Oct 5;268(28):21172–21184. [PubMed] [Google Scholar]
  53. Uzé G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990 Jan 26;60(2):225–234. doi: 10.1016/0092-8674(90)90738-z. [DOI] [PubMed] [Google Scholar]
  54. Waddell T., Cohen A., Lingwood C. A. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci U S A. 1990 Oct;87(20):7898–7901. doi: 10.1073/pnas.87.20.7898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Waddell T., Head S., Petric M., Cohen A., Lingwood C. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun. 1988 Apr 29;152(2):674–679. doi: 10.1016/s0006-291x(88)80091-3. [DOI] [PubMed] [Google Scholar]
  56. Wiels J., Fellous M., Tursz T. Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6485–6488. doi: 10.1073/pnas.78.10.6485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wiels J., Mangeney M., Tétaud C., Tursz T. Sequential shifts in the three major glycosphingolipid series are associated with B cell differentiation. Int Immunol. 1991 Dec;3(12):1289–1300. doi: 10.1093/intimm/3.12.1289. [DOI] [PubMed] [Google Scholar]
  58. Zhou L. J., Ord D. C., Hughes A. L., Tedder T. F. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J Immunol. 1991 Aug 15;147(4):1424–1432. [PubMed] [Google Scholar]
  59. de Rie M. A., Schumacher T. N., van Schijndel G. M., van Lier R. A., Miedema F. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol. 1989 Feb;118(2):368–381. doi: 10.1016/0008-8749(89)90385-7. [DOI] [PubMed] [Google Scholar]
  60. van de Kar N. C., Monnens L. A., Karmali M. A., van Hinsbergh V. W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood. 1992 Dec 1;80(11):2755–2764. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES